Your session is about to expire
← Back to Search
Laxative
2L Bi-Peglyte for Bowel Prep Efficacy
N/A
Waitlist Available
Led By Robert A Enns, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
Summary
The investigators wish to compare the efficacy and patient tolerability of a preparation consisting of 2L Bi-Peglyte plus 15mg of bisacodyl vs the standard preparation of 4L Peglyte. The investigators hypothesize that 2L Bi-Peglyte with 15mg bisacodyl will show higher efficacy and tolerability.
Eligible Conditions
- Bowel Prep Efficacy
- No changes made.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Difference in Boston Bowel Preparation Scale between the two groups
Secondary study objectives
Difference in the absolute number/percentage of participants in the two groups who find the bowel prep experience easy, acceptable, difficult, very difficult, or unable to complete.
Difference in the number of participants who develop distress symptoms from bowel prep (and the type) between the two groups
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: 2L Bi-PeglyteExperimental Treatment1 Intervention
Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
Group II: Standard bowel prepActive Control1 Intervention
Subject will receive standard bowel prep prior to colonoscopy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bisacodyl
FDA approved
Find a Location
Who is running the clinical trial?
University of British ColumbiaLead Sponsor
1,451 Previous Clinical Trials
2,482,872 Total Patients Enrolled
Robert A Enns, MDPrincipal InvestigatorThe University of British Columbia
Share this study with friends
Copy Link
Messenger